
Background The pervasive use of cell phones has led to a substantial increase in pulsed electromagnetic fields (EMFs) in our immediate environment. For pharmaceuticals, close proximity EMF effects are considered analogous to those of conventional heating, whilst the effect on homeopathic preparations remains inconclusive. Objectives Accordingly, we investigated whether pulsed EMF in the GHz range affects homeopathic preparations regarding their biological effects under real-world conditions. Methods Stannum metallicum 30x (nominal dilution 10 (-30) of the original substance), and lactose 30x as a control, were subjected to 14 hours of close proximity cell phone irradiation (2G, second-generation wireless technology, open vocal call) or remained untreated. The homeopathic samples were positioned in a circle at the perimeter of a rotating plate adjacent to the cell phone (minimal distance, d = 7 cm) to ensure homogeneous exposure. Biological effects were investigated in a Lepidium sativum (cress) bioassay, assessing four independent outcome parameters. Experiments were performed in parallel at two independent laboratories. Experimental stability was monitored throughout the entire investigation with systematic negative control (SNC) experiments. Results Untreated Stannum metallicum 30x exhibited significant effects compared to lactose 30x for all four outcome parameters in the bioassay used ( p <= 0.05), while the cell phone-irradiated samples induced no effects at all. No significant effects were observed in any of the evaluations of the SNC experiments, indicative of a stable experimental set-up and a reliable and specific treatment effect. Conclusion This is the first investigation that provides conclusive data that exposure of a homeopathic preparation to pulsed GHz EMF inactivates the homeopathic preparation regarding its biological effects. This finding cannot be extrapolated to other preparations or organisms, but warrants further investigation for potential implications in the clinical use of homeopathic preparations. Further in-depth follow-up studies under controlled laboratory conditions may contribute to substantiating hypotheses regarding the mode of action of ultra-molecular homeopathic preparations.
Abstract Rheumatoid arthritis (RA) is a chronic inflammatory disorder requiring long-term management. Individualized homeopathy has been proposed as a potential adjunct in integrative care, though clinical evidence is limited. The primary objective of the study was to evaluate the effect of homeopathic medicines in the management of RA using the Disease Activity Score 28 (DAS28). The secondary objective aimed to evaluate the activity profile and quality of life of patients using the American College of Rheumatology 20 (ACR20) response criteria. A multi-center, prospective, non-randomized, single-group interventional RA study included 134 patients diagnosed according to the 2010 ACR/European Alliance of Associations for Rheumatology (EULAR) criteria. Prescriptions were individualized based on classical homeopathic principles. The primary outcome, DAS28, was assessed at baseline and every 3 months for 12 months. Secondary outcomes were ACR20 response criteria measured monthly, covering tender and swollen joint counts, patient and physician global assessments, pain, and disability. The study was registered with the Clinical Trials Registry–India (CTRI/2018/01/011192). Of the 134 enrolled participants, 74 (55.2%) completed the 12-month follow-up for per-protocol analysis, reflecting 44.8% attrition. Statistically significant improvements (p < 0.01) were observed in DAS28 and ACR20 parameters. The baseline DAS28 score (5.03) indicated that the study sample had moderate-to-high RA disease activity, decreasing by 1.26 points at 9 months and by 1.31 points at 12 months, reflecting an improvement over time. ACR20 response included a 40% reduction in tender joints, 90% reduction in swollen joints, and improvements in patient global assessment (77%), physician global assessment (77%), pain (75%), and disability (65%). Symptomatic assessments supported these outcomes. Rhus toxicodendron, Pulsatilla, and Phosphorus were commonly prescribed medicines. Individualized homeopathic treatment resulted in positive outcomes for disease activity and patient-reported outcomes over 12 months, without disease-modifying anti-rheumatic drug use. Findings suggest a potential role for individualized homeopathy in integrative RA management, warranting further investigation in controlled trials.
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with frequent renal involvement that significantly influences disease prognosis. Class II mesangial lupus nephritis represents an early histopathological stage and may present with persistent proteinuria and recurrent disease flares. Conventional long-term management often requires prolonged corticosteroid and immunosuppressive therapy, which may lead to adverse effects and therapeutic dependency. Case Summary A 20-year-old male with SLE and biopsy-proven Class II mesangial lupus nephritis presented with recurrent febrile episodes, fatigue, weight loss, thrombocytopenia and persistent proteinuria, despite extended treatment with corticosteroids, mycophenolate mofetil and hydroxychloroquine. Individualized homeopathic treatment was initiated in February 2022 following a comprehensive constitutional assessment. Lycopodium clavatum was prescribed as the principal remedy, with Serum anguillae used supportively during periods of urinary involvement, in accordance with classical homeopathic principles. The patient was followed clinically and through periodic laboratory investigations for over 3 years. Results During follow-up, the frequency and intensity of febrile episodes gradually declined, with improvement in appetite, body weight and overall well-being. Laboratory findings demonstrated improvement in platelet counts and relative stabilization of renal parameters, including reduction in proteinuria and protein-creatinine ratio over time. Corticosteroids were tapered and eventually discontinued under specialist supervision without major documented exacerbation. Causal attribution assessment using the MONARCH inventory yielded a total score of +8, suggesting a temporal association between the individualized homeopathic intervention and the observed clinical course. Conclusion This case report describes a temporal association between adjunctive individualized homeopathic treatment and clinical stabilization in Class II mesangial lupus nephritis. The findings should be interpreted cautiously. This report does not support the replacement of standard-of-care therapy but suggests a possible supportive role that warrants further systematic investigation.
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Identification of potential therapeutic strategies and molecular targets requires evaluation in robust preclinical models. Several homeopathic preparations have been reported to influence proliferation, apoptosis, and oxidative signaling in cancer cell models. Arsenicum iodatum ( Ars. iod ), a homeopathic preparation traditionally associated with degenerative and cachectic conditions and clinically used in some HCC patients at the Government Homoeopathic Cancer Centre, Kerala, has not previously been evaluated at the cellular level. The aim of this study was therefore to perform a preliminary investigation of the effects of Ars. iod on the human HCC cell line HepG2 in vitro . Methods HepG2 cells were treated with Ars. iod at three potencies (6C, 12C, and 30C) and compared with untreated control cells. An ethanol-matched vehicle control was used in initial cytotoxicity studies. Cellular responses were assessed using the MTT cell-viability assay, acridine orange/ethidium bromide (AO/EtBr) staining for apoptotic morphology, propidium iodide staining with flow cytometry for cell cycle analysis and indirect ELISA for caspase-3 and caspase-7 protein expression. Experiments were performed in biological triplicate and statistically analyzed. Results Treatment with Ars. iod was associated with reduced HepG2 cell viability after 24 hours. The calculated IC 50 values for the 6C, 12C, and 30C potencies were 59.36, 38.47, and 31.86 mu L/mL, respectively, compared with 55.19 mu L/mL for the vehicle control. Cell cycle analysis demonstrated redistribution of cells across different phases following treatment, with 6C associated with accumulation in the G 2 /M phase, 12C with increased S-phase population, and 30C with redistribution across both G (0) /G (1) and G (2) /M phases. AO/EtBr staining, together with elevated caspase-3 and caspase-7 protein expression levels, confirmed that Ars. iod was capable of inducing apoptosis in HepG2 cells. Conclusion Under controlled in vitro conditions, homeopathic Ars. iod potencies were associated with potency-dependent cytotoxic, cell cycle perturbation, and apoptotic effects in HepG2 cells. These findings provide preliminary evidence supporting further investigation of the biological effects and underlying mechanisms of Ars. iod in HCC models.
Background In homeopathy, symptoms are central to remedy selection and are traditionally validated through clinical experience and materia medica descriptions. Prognostic factor research using likelihood ratios (LRs) offers a quantitative approach to determine how strongly individual symptoms predict treatment response. This study evaluated the prognostic relevance of four commonly described symptoms of Carcinosin -history of tuberculosis, sleeplessness, enjoyment of watching a thunderstorm, and artistic personality-using LR and Bayesian methods. Methods This analytical, longitudinal, real-world study was conducted in the outpatient departments of an Indian homeopathic hospital. Adults with chronic diseases of at least 1 year's duration were included. Clinical outcomes were assessed using the Outcome Related to Impact on Daily Living (ORIDL) scale, with scores >= 2 indicating meaningful improvement. For each symptom, 2 & times; 2 contingency tables were constructed, and positive and negative LRs with 95% confidence intervals (CIs) were calculated for four Carcinosin symptoms. A Bayesian updating simulation was performed to estimate cumulative diagnostic probability from sequential symptom combinations. Results Since 20 participants in the other-medicines group were lost to follow-up, a total of 1,614 participants were analyzed, of whom 128 received Carcinosin . The highest prognostic strength was observed for enjoyment of watching a thunderstorm (LR+ 5.6, 95% CI 4.5-7.0) and artistic personality (LR+ 4.6, 95% CI 3.7-5.8). Sleeplessness showed moderate association (LR+ 2.0, 95% CI 1.7-2.3), while history of tuberculosis demonstrated weak to modest discriminative value (LR+ 1.4, 95% CI 1.1-1.9). Bayesian updating indicated that behavioral symptoms produced the largest upgrade in posterior probability, reaching approximately 79% when all four symptoms were sequentially combined. Conclusion Behavioral and personality-based symptoms provided substantially stronger prognostic support for Carcinosin prescribing than historical or general physical features. LR and Bayesian frameworks offered a practical, quantitative method for validating materia medica symptoms and refining individualized homeopathic prescribing.